Skip to Content

What is Nucala (mepolizumab) used for and how is it given?

Medically reviewed by Judith Stewart, BPharm. Last updated on Sep 28, 2020.

Official Answer


Nucala (mepolizumab) is a biologic therapy used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). It is given by subcutaneous injection every four weeks.

Nucala is an interleukin-5 (IL-5) antagonist monoclonal antibody indicated for the:

  • add-on maintenance treatment of patients aged 6 years and older with severe eosinophilic asthma whose asthma is not controlled with their current asthma medicines. Nucala helps prevent severe asthma attacks (exacerbations).
  • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Nucala helps reduce symptoms and flares and may allow for a reduction in their oral corticosteroid medicine.
  • treatment of patients 12 years of age and older with hypereosinophilic syndrome (HES). Nucala helps reduce symptoms and prevent flares.

Nucala is an injectable medication given by subcutaneous injection (under the skin) every 4 weeks.

Nucala is supplied as a single-dose prefilled autoinjector or a single-dose prefilled syringe. The injection may be administered by a health care provider or patient caregiver, or self-administered by patients who are 12 years of age and older.

Patients should inject Nucala into their thigh or stomach (abdomen). A health care provider or patient caregiver may also give the injection in the upper arm.

You will find detailed information at Nucala - FDA Prescribing Information including Instructions for Use (at the bottom of the page).

Related Medical Questions

Drug Information

Related Support Groups